Official Title
Effectiveness Evaluation of the Sinopharm Vaccine in the Dondo District in Mozambique
Brief Summary

Three complementary activities will be implemented:1) Baseline and repeat census of thecatchment population; described in a separate protocol (IVI-ECOVA-03-WS1); 2) Enhancedsurveillance for COVID-19 disease, and 3) AEFI-enhanced surveillance. The massvaccination campaign will be conducted by the Government and is not part of thisprotocol.

Detailed Description

Not Provided

Recruiting
SARS-CoV-2 Infection

Other: Sinopharm Vaccine

Sinopharm Vaccine will be administered by the Govt as part of COVID-19vaccination
campaign

Eligibility Criteria

Inclusion Criteria:

1. They resided in the study area at the time of mass immunization with the Sinopharm
vaccine; and

2. They are at least 18 years of age during first round of mass vaccination.

3. Their onset of symptoms was <10 days prior to testing.

4. For each selected PCR test-positive case, we will select up to 3 test-negative
controls from generally eligible subjects, matched to each case by age on the date
of testing, sex, and calendar date of testing + 3 days.

Exclusion Criteria:

1. We will exclude subjects for selection as controls if they have had a positive test
result within the following 21 days

2. Any Participant not matching the inclusion criteria mentioned above.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Mozambique
Locations

Dondo Health Facility
Dondo, Mozambique

Investigator: Ilesh Jani, PhD
Contact: +258825802221
ilesh.jani@ins.gov.mz

Contacts

Florian Marks, PhD
+821087033813
fmarks@ivi.int

Birkneh Tilahun Tadesse, PhD
+821098041348
birkneh.tadesse@ivi.int

Not Provided

International Vaccine Institute
NCT Number
MeSH Terms
COVID-19